Autopsy report · NCT05045404
Poziotinib and Ramucirumab for the Treatment of EGFR Exon 20 Mutant Stage IV Non-small Cell Lung Cancer
Cause of deathSlow enrollment, also funding or business
“Study closed due to funding, 0 patient accrual.”
Life of this trial
- Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.
Vital statistics
- Status
- Withdrawn
- Phase
- Phase 2
- Sponsor
- M.D. Anderson Cancer Center
- Sponsor type
- University, hospital or other
- Conditions
- Metastatic Lung Non-Small Cell Carcinoma; Stage IV Lung Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8
- Interventions
- Poziotinib Hydrochloride; 1429757-68-5, HM781-36B, NOV-1201 Hydrochloride, NOV120101 Hydrochloride, Poziotinib HCl, POZIOTINIB HYDROCHLORIDE
- Participants
- 0
Trials that died the same way
- Adipose Derived SVF for Aero-digestive & Enterocutaneous Fistulae
“Study closed due to lack of patient enrollment.” - A Phase 1, Open-Label Study of Intravenous Sildenafil in Patients With Cirrhosis
“The study is closed due to lack of funding to support the study.” - Autoantibodies in Breast Cancer Detection
“Study closed to enrollment and data and specimen collection due to lack of funding.” - Changes in Bone Turnover With Increased Incretin Hormone Exposure
“Study closed by sponsor. Funding ended.” - Treosulfan-Based Versus Clofarabine-Based Conditioning Before Donor Hematopoietic Stem Cell Transplant for the Treatment of Myelodysplastic Syndromes or Acute Myeloid Leukemia
“The study was closed due to the end of funding.”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.